A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 with FOLFOX plus Cetuximab versus FOLFOX with or without Bevacizumab as First-line Treatment of Participants with KRAS G12C Mutant, Metastatic Colorectal Cancer

Principal Investigator

Dr Victoria Woodcock

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1011282